Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL)
January 06, 2020 08:00 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences to Present at Biotech Showcase 2020
December 19, 2019 08:00 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study
December 16, 2019 08:00 ET
|
Cellectar Biosciences
30% overall response rate seen with an average progression free survival of 4.5 months and an acceptable and expected safety profile Additional data in patients receiving higher fractionated doses of...
Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium
December 13, 2019 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology Conference
December 09, 2019 08:30 ET
|
Cellectar Biosciences
50% overall response rate in cohort of patients receiving fractionated 37.5 mCi/m2 dose of CLR 131 31.3% overall response rate in multiple myeloma patients over all dose levels, including single bolus...
Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference
December 02, 2019 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Cellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate Update
November 12, 2019 08:00 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Cellectar Presents a New Phospholipid Drug Conjugate (PDC) at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
October 30, 2019 08:00 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
October 17, 2019 08:00 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Cellectar Presents Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology
October 15, 2019 08:00 ET
|
Cellectar Biosciences
Data demonstrate phospholipid ether (PLE) molecules ability to target wide range of tumors FLORHAM PARK, N.J., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a...